Clinical Trials Directory

Trials / Completed

CompletedNCT00511719

Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes

A Prospective, Controlled, Single-Center, Open-Label,Randomized, Replicated, Crossover Isoglycemic Glucose Clamp Study Evaluating Intrapatient Variability in Bioavailability of Technosphere® Insulin Compared With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Mannkind Corporation · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the kinetics and biodynamics of inhaled Technosphere Insulin with those of subcutaneous (SC) regular human insulin.

Conditions

Interventions

TypeNameDescription
DRUGTechnosphere Insulin48U
DRUGActrapid24IU

Timeline

Start date
2004-02-01
Primary completion
2004-04-01
Completion
2005-03-01
First posted
2007-08-06
Last updated
2011-06-29

Source: ClinicalTrials.gov record NCT00511719. Inclusion in this directory is not an endorsement.

Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes (NCT00511719) · Clinical Trials Directory